GENSCRIPT BIO (01548.HK) plans to issue in total 77.13 million shares by placement, with estimated net proceeds of HKD 2.33 billion

NewTimeSpace (newtimespace.com) News, GENSCRIPT BIO (01548.HK) announced on Sep 11, 2026 that the company has entered into a placement agreement with the placement agent on Sep 11, 2026. According to the agreement, the placing agent conditionally agreed to use its best endeavors to procure placees to subscribe for in total 77.13 million shares placement, which represent approximately 3.5% of the company's existing issued share capital as of the date of this announcement, and approximately 3.38% after the subscription.
The placement price per share is HKD 30.5. The total proceeds from the placement are estimated to be about HKD 2.35 billion. After deducting the placement commission, professional fees, and all related expenses that the company may incur, the net proceeds from the placement are estimated to be approximately HKD 2.33 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.